InDex Pharmaceuticals Holding AB financials
InDex Pharmaceuticals Holding AB
54930047C4A74IBXR037 | Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | SEK 100.0K | SEK 0 |
| Other income | SEK 3.7M | SEK 4.6M |
| Employee benefits expense | SEK 21.2M | SEK 11.7M |
| Operating profit (EBIT) | -SEK 275.0M | -SEK 571.1M |
| Net finance income / (cost) | SEK 47.1M | SEK 9.7M |
| Finance costs | SEK 6.2M | SEK 22.3M |
| Profit before tax | -SEK 227.9M | -SEK 561.5M |
| Income tax expense | SEK 100.0K | -SEK 1.9M |
| Profit for the year | -SEK 228.0M | -SEK 559.6M |
| — attributable to owners | -SEK 228.0M | -SEK 559.6M |
| Total comprehensive income | -SEK 228.0M | -SEK 559.6M |
| Per share | ||
| Basic EPS | SEK -3.24 | SEK -11.34 |
| Cash flow statement | ||
| Net cash from operating activities | -SEK 17.0M | -SEK 73.8M |
| Net cash from investing activities | -SEK 19.8M | -SEK 625.2M |
| Net cash from financing activities | SEK 571.9M | SEK 634.7M |
| Proceeds from borrowings | SEK 90.0M | SEK 635.1M |
| Repayments of borrowings | SEK 90.0M | SEK 0 |
| Lease liability payments | SEK 400.0K | SEK 400.0K |
| Balance sheet | ||
| Total assets | SEK 4.22B | SEK 3.58B |
| Non-current assets | SEK 3.20B | SEK 3.14B |
| Property, plant & equipment | SEK 1.0M | SEK 1.6M |
| Right-of-use assets | SEK 800.0K | SEK 1.2M |
| Current assets | SEK 1.02B | SEK 447.4M |
| Trade & other receivables | SEK 800.0K | SEK 100.0K |
| Cash & equivalents | SEK 865.1M | SEK 330.0M |
| Total equity | SEK 4.20B | SEK 3.57B |
| Non-current liabilities | SEK 6.7M | SEK 6.4M |
| Lease liabilities (non-current) | SEK 400.0K | SEK 900.0K |
| Current liabilities | SEK 18.5M | SEK 11.2M |
| Lease liabilities (current) | SEK 400.0K | SEK 400.0K |
| Deferred tax liabilities | SEK 4.9M | SEK 5.5M |
| Derived metrics | ||
| Operating margin | -275000.0% | — |
| Net margin | -228000.0% | — |
| Return on equity | -5.4% | -15.7% |
| Cash conversion ratio | 0.07× | 0.13× |
| Other reported items | ||
| Additional Paidin Capital | SEK 5.50B | SEK 4.79B |
| Adjustments For Decrease Increase In Other Operating Receivables | SEK 13.5M | SEK 4.4M |
| Adjustments For Decrease Increase In Trade Account Receivable | -SEK 600.0K | SEK 0 |
| Adjustments For Fair Value Gains Losses | SEK 176.9M | SEK 532.8M |
| Adjustments For Increase Decrease In Other Operating Payables | -SEK 1.7M | -SEK 40.6M |
| Cash Flows From Used In Operations Before Changes In Working Capital | -SEK 28.2M | -SEK 37.6M |
| Comprehensive Income Attributable To Owners of Parent | -SEK 228.0M | -SEK 559.6M |
| Current Accrued Expenses and Other Current Liabilities | SEK 5.6M | SEK 2.4M |
| Current Financial Assets At Fair Value Through Profit Or Loss | SEK 57.1M | SEK 95.9M |
| Current Prepayments and Current Accrued Income Including Current Contract Assets | SEK 1.3M | SEK 1.1M |
| Current Tax Assets Current | SEK 9.4M | SEK 2.4M |
| Current Tax Liabilities Current | SEK 100.0K | SEK 0 |
| Deferred Tax Assets | SEK 500.0K | SEK 800.0K |
| Depreciation Expense | SEK 800.0K | SEK 600.0K |
| Equity and Liabilities | SEK 4.22B | SEK 3.58B |
| Finance Income | SEK 53.3M | SEK 31.9M |
| Gains Losses On Financial Assets At Fair Value Through Profit Or Loss Mandatorily Measured At Fair Value | -SEK 176.9M | -SEK 532.8M |
| Gains On Disposals of Investments | SEK 8.1M | SEK 0 |
| Income Taxes Paid Refund Classified As Operating Activities | SEK 7.7M | SEK 2.1M |
| Increase Decrease In Cash and Cash Equivalents | SEK 535.1M | -SEK 64.2M |
| Increase Decrease In Working Capital | -SEK 11.2M | SEK 36.2M |
| Increase Decrease Through Other Contributions By Owners | — | SEK 1.21B |
| Increase Decrease Through Sharebased Payment Transactions | SEK 200.0K | — |
| Increase Decrease Through Transactions With Owners | SEK 860.2M | SEK 3.51B |
| Interest Paid Classified As Operating Activities | SEK 0 | SEK 41.6M |
| Interest Received Classified As Operating Activities | SEK 16.6M | SEK 6.6M |
| Issue of Equity | SEK 572.3M | SEK 2.30B |
| Issued Capital | SEK 156.1M | SEK 600.0K |
| Miscellaneous Other Operating Expense | SEK 68.3M | SEK 3.6M |
| Noncurrent Financial Assets | SEK 3.20B | SEK 3.13B |
| Noncurrent Financial Assets At Fair Value Through Profit Or Loss Mandatorily Measured At Fair Value | SEK 3.07B | SEK 2.80B |
| Noncurrent Receivables Due From Related Parties | SEK 125.3M | SEK 330.5M |
| Other Adjustments For Noncash Items | SEK 30.4M | -SEK 6.9M |
| Other Comprehensive Income | SEK 0 | SEK 0 |
| Other Current Receivables | SEK 2.4M | SEK 2.0M |
| Other Expense By Nature | SEK 19.7M | SEK 27.1M |
| Other Noncurrent Financial Assets | SEK 100.0K | SEK 100.0K |
| Other Noncurrent Financial Liabilities | SEK 1.5M | SEK 0 |
| Other Payables | SEK 11.8M | SEK 100.0K |
| Payments For Share Issue Costs | SEK 34.9M | SEK 0 |
| Proceeds From Issuing Shares | SEK 607.2M | SEK 0 |
| Proceeds From Sales of Investments Other Than Investments Accounted For Using Equity Method | SEK 49.1M | SEK 2.2M |
| Purchase of Investments Other Than Investments Accounted For Using Equity Method | SEK 485.3M | SEK 622.1M |
| Purchase of Other Longterm Assets Classified As Investing Activities | SEK 0 | SEK 0 |
| Retained Earnings | -SEK 1.45B | -SEK 1.23B |
| Trade and Other Current Payables To Related Parties | SEK 0 | SEK 7.4M |
| Trade and Other Current Payables To Trade Suppliers | SEK 600.0K | SEK 800.0K |
| Trade and Other Current Receivables Due From Related Parties | SEK 88.7M | SEK 15.9M |
Every line item above is a fact tagged in InDex Pharmaceuticals Holding AB's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (SEK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.